Blood News and Research

RSS

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Mosquito screens prevent malaria

Trials of a screen-based malaria prevention programme in 500 homes in The Gambia, Africa, have led to a 50 per cent reduction in malaria transmission and anaemia in children. A child dies from malaria in Africa every 30 seconds and infection can lead to an increased risk of anaemia, which can also prove fatal. Yet to date, screens have often been ignored in favour of using drugs and insecticides.

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

New device for treating hypoglycemia launched globally

At this year’s annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Ljubljana, Slovenia, Medtronic, Inc. announced the global launch of a novel technology designed to provide additional protection against the risks associated with hypoglycemia.

3 Sep 2009

m.pulse system for MCP therapy installed in ten hospitals

Cardiola AG announced today that it has placed its patented m.pulse system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse is the world’s first and only device enabling CAD patients to receive MCP therapy at home.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

3 Sep 2009

Increase in Rifampicin dosage shortens tuberculosis treatment duration

According to Dutch researcher Hanneke Later-Nijland, it may be possible to shorten the duration of treatment for tuberculosis. Due to the long duration of treatment, not every patient sees it through. Partly because of this, tuberculosis is one of the most lethal diseases in developing countries.

3 Sep 2009

Research reveals that 21% of death claims are rejected by California's largest private insurers

More than one of every five requests for medical claims for insured patients, even when recommended by a patient's physician, are rejected by California's largest private insurers, amounting to very real death panels in practice daily in the nation's biggest state, according to data released today by the California Nurses Association/National Nurses Organizing Committee.

3 Sep 2009

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

The decision by a Pfizer sales representative in Florida to file a whistleblower ("qui tam") lawsuit in 2003 kicked off the federal and state investigations that led to Pfizer's record-breaking $2.3 billion settlement today.

3 Sep 2009

Alloantigen-specific Treg cells targeted for organ transplantation

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

Players’ fencing response yields visual clues on brain injury

Brain injury researchers at the University of Kentucky have spent hundreds of hours watching YouTube videos of people getting smacked, punched and knocked in the head during sporting events and recreational activities. But those researchers weren't goofing off on the Internet; they were doing hard science.

3 Sep 2009

Scientists demonstrate the link between cancer and diesel fumes

Scientists here are the first to demonstrate that the link between diesel fume exposure and cancer lies in the ability of diesel exhaust to induce the growth of new blood vessels that serve as a food supply for solid tumors.

2 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Irregular heartbeat is a common cause of stroke

Mellanie True Hills knows personally the toll that atrial fibrillation (afib) takes. Just two years ago, with a sense of urgency about afib that only a survivor can possess, she designated September as Atrial Fibrillation Month.

2 Sep 2009

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Novo Nordisk's NCDP provides support for accurate cost and benefit assessments of preventive health

The National Changing Diabetes((R) )Program (NCDP), a program of Novo Nordisk, commends Representative Donna M. Christensen, M.D. (D-VI) and Michael C. Burgess, M.D. (R-TX) for sponsoring legislation that will lead to a more accurate assessment of the cost and benefits of preventive health, including preventing complications and delaying progression of chronic diseases such as diabetes.

From Novo Nordisk 2 Sep 2009

Telemedical supervision for chronic heart failure patients reduces hospital expenses

The current data confirms previous health economic evaluations: If patients with chronic heart failure are receive telemedical supervision, this means that they will require less and shorter hospital care. In this study hospital expenses dropped by around 70 percent in a year.

2 Sep 2009

Blood News and Research

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Mosquito screens prevent malaria

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

New device for treating hypoglycemia launched globally

m.pulse system for MCP therapy installed in ten hospitals

GDC-0449 inhibits the Hedgehog signaling pathway

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Increase in Rifampicin dosage shortens tuberculosis treatment duration

Research reveals that 21% of death claims are rejected by California's largest private insurers

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

Alloantigen-specific Treg cells targeted for organ transplantation

Avastin increases survival rates in recurrent glioblastoma affected patients

Players’ fencing response yields visual clues on brain injury

Scientists demonstrate the link between cancer and diesel fumes

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Irregular heartbeat is a common cause of stroke

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

Novo Nordisk's NCDP provides support for accurate cost and benefit assessments of preventive health

Telemedical supervision for chronic heart failure patients reduces hospital expenses

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News